Tango Therapeutics, Inc (TNGX)
26.80
+1.55 (6.14%)
Upcoming Events
Latest Headlines
Tango Therapeutics to present cancer drug combo data at ESMO 2026
October 16, 2026 7:01 AM - StreetInsider
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
October 16, 2026 7:00 AM - StreetInsider
William Blair Starts Tango Therapeutics Inc. (TNGX) at Outperform
October 15, 2026 4:56 PM - StreetInsider
JPMorgan Adds Positive Catalyst Watch on Tango Therapeutics Inc. (TNGX)
October 13, 2026 7:58 AM - StreetInsider
Form 4 Tango Therapeutics, Inc. For: Oct 01 Filed by: Crystal Adam
October 5, 2026 5:37 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Sep 22 Filed by: Newcomb Jessica
September 24, 2026 7:42 PM - SEC Filing
Form 144 Tango Therapeutics, Inc. Filed by: Newcomb Jessica
September 22, 2026 4:14 PM - SEC Filing
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026 4:05 PM - StreetInsider
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 1, 2026 7:00 AM - StreetInsider
Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright
August 18, 2026 6:39 AM - StreetInsider
Tango Therapeutics Inc. (TNGX) Reiterated at Buy by Stifel: 3 Catalysts by YE26
August 17, 2026 7:49 AM - StreetInsider
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.
August 14, 2026 4:49 PM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC
August 14, 2026 4:20 PM - SEC Filing
Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC
August 14, 2026 2:12 PM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP
August 14, 2026 11:05 AM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 14, 2026 8:24 AM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
August 12, 2026 12:02 PM - SEC Filing
Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim
August 12, 2026 6:53 AM - StreetInsider
Form 8-K Tango Therapeutics, Inc. For: Aug 11
August 11, 2026 5:13 PM - SEC Filing
Form 424B5 Tango Therapeutics, Inc.
August 11, 2026 5:11 PM - SEC Filing
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
August 11, 2026 11:01 AM - StreetInsider
Tango Therapeutics, Inc. (TNGX) Misses Q2 EPS by 5c
August 11, 2026 7:27 AM - StreetInsider
Form 8-K Tango Therapeutics, Inc. For: Aug 11
August 11, 2026 7:21 AM - SEC Filing
Form 10-Q Tango Therapeutics, Inc. For: Jun 30
August 11, 2026 7:13 AM - SEC Filing
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026 7:00 AM - StreetInsider
Form 8-K/A Tango Therapeutics, Inc. For: Jul 31
August 7, 2026 6:42 AM - SEC Filing
Tango Therapeutics Announces Executive Chair Transition
August 6, 2026 6:24 PM - Globe NewsWire
Form 8-K Tango Therapeutics, Inc. For: Jul 31
August 6, 2026 5:30 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Aug 03 Filed by: Crystal Adam
August 5, 2026 4:01 PM - SEC Filing
Form 144 Tango Therapeutics, Inc. Filed by: Crystal Adam
August 3, 2026 4:47 PM - SEC Filing
Full Article List
